Publications by authors named "Johan P Kuijvenhoven"
Article Synopsis
- * A study analyzed 200 individuals with Lynch syndrome to assess the effectiveness of faecal VOCs, both alone and in combination with FIT, in identifying relevant colorectal neoplasia before and after colonoscopy.
- * Results indicated high sensitivity and negative predictive values for detecting colorectal cancer and advanced adenomas using VOC analysis, suggesting that faecal VOCs could guide optimal colonoscopy intervals and improve patient monitoring following polypectomy.
Article Synopsis
- Colonoscopy surveillance for individuals with Lynch syndrome is challenging, and colorectal cancers can still occur despite regular screenings.
- A study evaluated the efficacy of fecal immunochemical tests (FIT) to determine the best intervals for colonoscopy by measuring specific thresholds of hemoglobin in stool samples.
- Results indicated that using a lower FIT threshold (2.5 μg Hb/g) increased the detection rate of relevant neoplasia, with even better specificity seen at a threshold of 4.1 μg Hb/g, suggesting that FIT could potentially allow many Lynch syndrome patients to delay unnecessary colonoscopies while still effectively identifying those at risk for advanced neoplasia.
Article Synopsis
- This study looked at how safe the medicine allopurinol is for pregnant women, especially those with a condition called inflammatory bowel disease (IBD).
- Researchers gathered data from 42 pregnancies where mothers took allopurinol and found some complications, like miscarriages and a baby born with a heart issue.
- Overall, the findings suggest that allopurinol might not significantly increase the risk of birth defects in babies born to mothers with IBD who took this medicine.
Background: Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth.
Methods: In this multicentre case series, IBD patients treated with thioguanine during pregnancy were included.
Background: Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking. This study aims to demonstrate noninferiority for QoL and efficacy after switching.
Methods: OoL and clinical efficacy were measured prior to and after 2, 4, and 6 CT-P13 infusions.